BPC-157 + TB-500 (Wolverine Stack) Reconstitution Calculator & Dosage Protocol for Injury Recovery

Two Vials, Two Schedules

BPC-157 and TB-500 use different dose scales and schedules: BPC-157 runs daily in micrograms, while TB-500 runs 2–3× weekly in milligrams. Separate vials preserve that distinction. A premixed vial reduces handling but fixes the ratio and puts both peptides on one schedule.

The two peptides target different repair bottlenecks. BPC-157 supports new capillary growth and blood supply; TB-500 supports the movement of repair cells that organize new tissue.¹ ² The stack pairs perfusion with cell migration.

No human trial has tested the combination. BPC-157 evidence is predominantly preclinical, with one 12-patient clinical study.³ The Phase 1 human safety data belongs to full-length TB-4, not automatically to the TB-500 fragment.⁴ The protocol comes from component mechanisms and practitioner use rather than a controlled trial of the pair.

For the mechanism deep-dives, see the standalone guides: BPC-157 and TB-500 / TB-4. For the narrative injury-recovery walkthrough, see the Wolverine Stack guide.

How Wolverine Stack Doses and Reconstitution Are Calculated

The vial format determines the calculation. Individual vials are reconstituted separately and retain independent schedules. A combined vial needs one reconstitution, but every draw delivers both peptides at the supplied ratio and couples their schedules.

Every case below uses the same formula:

$$V_{\text{draw}}=\frac{D\times V_{\text{water}}}{M}$$

$V_{\text{draw}}$ is the syringe draw (mL), $D$ the target dose, $V_{\text{water}}$ the BAC water added (mL), and $M$ the vial mass of the compound being solved for. Match the units of $D$ and $M$: both mg, or both mcg.

Path 1: individual vials

Reconstitute each vial separately, then dose on its own schedule.

BPC-157: 500 mcg daily

The two common vial sizes both land on a 10-unit draw:

$$V_{\text{draw}}=\frac{500\text{ mcg}\times 1\text{ mL}}{5000\text{ mcg}}=0.1\text{ mL}=10\text{ units on a U-100 syringe}$$

A 250 mcg dose uses half the listed draw: 0.05 mL (5 units).

TB-500: 2.5 mg 2–3× weekly

Both common vial sizes land on a 50-unit draw:

$$V_{\text{draw}}=\frac{2.5\text{ mg}\times 2\text{ mL}}{10\text{ mg}}=0.5\text{ mL}=50\text{ units on a U-100 syringe}$$

A 2 mg dose uses 0.4 mL (40 units) with either reconstitution.

On overlap days, practitioner protocols sometimes co-draw BPC-157 and TB-500 because their solutions are pH-compatible. NAD+ requires a separate syringe and site because its acidity can degrade peptides on contact.

Path 2: combined blend vial

A blend vial holds both peptides at a fixed mass ratio. One reconstitution sets both doses, and every draw delivers the pair on one schedule.

Standard 1:1 blends

Equal-mass blends are commonly labeled 5/5 or 10/10. A "10 mg Wolverine Stack" contains 5 mg of each peptide; a "20 mg" vial contains 10 mg of each.

Because the ratio is 1:1, a daily 0.1 mL draw keeps BPC-157 in its usual 500 mcg range but delivers TB-500 every day rather than pulsed 2–3× weekly. That is the blend tradeoff; separate vials (Path 1) avoid it.

Custom blends

When the masses are unequal, one peptide becomes the dose anchor and the other scales with the vial ratio. This is the same anchor math used by the KLOW calculator.

Example — a 10 mg BPC-157 / 5 mg TB-500 vial (a 2:1 blend), anchored to 500 mcg BPC-157, reconstituted in 2 mL:

$$V_{\text{draw}}=\frac{0.5\text{ mg}\times 2\text{ mL}}{10\text{ mg}}=0.1\text{ mL}=10\text{ units}$$

That same 0.1 mL draw also delivers 250 mcg TB-500 — half the BPC-157 dose, by the 2:1 ratio.

The calculator above solves either path — individual vials or a blend at any ratio — for any vial size or target dose.

Dosing Protocol

The higher BPC-157 dose is the escalation range. TB-500 doses are distributed across the week; NAD+ is a conditional add-on for chronic, post-surgical, or energy-limited recovery.

Cycle length: 8–12 weeks for BPC-157, 6–10 weeks for TB-500. TB-500 can taper to once weekly after week 6 if the injury is stable.

Cycle structure

BPC-157 stays daily throughout; TB-500 front-loads, then tapers as the tissue starts holding.

Why BPC-157 is daily and TB-500 is not

BPC-157 delivers a signal. A small daily dose triggers repair cascades — new blood vessel formation, nitric oxide production, repair-cell migration — that keep running after the peptide itself clears.¹ Daily dosing keeps that signaling environment switched on.

TB-500 follows a concentration-dependent mechanism rather than a small daily signal.² Practitioner protocols therefore use milligram-scale doses 2–3× weekly, front-loading 3–4 mg through weeks 1–4 and tapering as the tissue stabilizes. Doses below that protocol range may not reach the proposed concentration threshold.

Weekly schedule

Specific weekdays matter less than distributing 2–3 TB-500 doses across the week. The examples show Monday/Thursday and Monday/Wednesday/Friday schedules. NAD+ remains in a separate syringe and site.

Injection routing

Near-injury injection, where easy and safe to reach, is the convention. Neither peptide "stays local" — both enter systemic circulation within minutes — but local injection may give a higher first-pass tissue concentration before that dilution.⁵ Safe placement matters more than a perfect site: for hard-to-reach injuries (spine, deep hip), abdomen or thigh works. See Where to Inject Peptides for the full breakdown.

How the Stack Works

Healing stalls when two things fail at once: the blood supply to the injury closes down, and the repair cells that rebuild tissue cannot move into position. The stack assigns one peptide to each problem.

BPC-157: blood supply

BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice. Preclinical research associates it with new capillary growth, nitric oxide signaling, and the FAK-paxillin pathway involved in repair-cell attachment and migration.¹ ⁶ These mechanisms provide the rationale for its use as the perfusion component of the stack.

TB-500: repair-cell movement

TB-500 is usually the thymosin beta-4 fragment 17–23, the short sequence tied to repair-cell movement. Every cell has internal scaffolding made of actin; TB-500 supports the actin-side signal repair cells use to migrate into damaged tissue (actin-binding repair signal).² These proposed roles are the rationale for pairing it with BPC-157.

One caution on identity: TB-500 (the fragment) and full-length TB-4 (43 amino acids) are related but not interchangeable, and product labels blur the two routinely.⁷ The stronger anti-scarring and tissue-remodeling claims come from full-length TB-4 research, not the isolated fragment. If scar remodeling is the goal, confirm the molecular weight on the certificate of analysis: around 800 Da is the fragment, around 4,900 Da is full-length. See the TB-500 guide for the full distinction.

Why the two mechanisms are paired

The evidence supports pairing the mechanisms, but not deterministic outcomes for every missing or combined component. Preclinical BPC-157 work supports blood-vessel and repair-cell signaling, while TB-500/TB-4 research supports cell migration.¹ ² Neither evidence base establishes that BPC-157 alone causes scar or adhesions or that the pair produces "organized tissue reconstruction" in humans.

In one rat model, combined BPC-157 + TB-4 restored contractile function earlier than either compound alone.⁸ That result supports further study of the pairing; it does not establish a human tissue outcome.

What the Wolverine Stack Is Not For

The stack clears a coupled perfusion-and-migration bottleneck: BPC-157 restores blood flow, while TB-500 supports repair-cell movement. That pairing fits tendon, ligament, muscle, fascia, joint capsule, and scar or connective tissue. It does not address tissues governed by different repair biology.

Bone and fracture repair. Mineralization, callus formation, and bone-matrix remodeling set the pace. Neither peptide directly supplies that mechanism.

Isolated cartilage. Cartilage has no blood supply to restore. Chondrocyte and matrix biology govern repair, and a systemic SubQ stack does not target a focal joint surface. Cartalax is the cartilage-specific option covered elsewhere in the library.

Peripheral nerve. Axonal regrowth depends on Schwann-cell and neurotrophic signaling rather than perfusion alone. ARA-290 is the nerve-repair compound covered by PeptideFox.

Central nervous system. Stroke and traumatic brain injury require blood-brain-barrier access and CNS-specific signaling. BPC-157 and TB-500 are peripheral repair peptides; Semax is the CNS-active option covered by PeptideFox.

Both peptides show isolated preclinical signals in spinal-cord-injury models. That evidence supports describing the Wolverine Stack as a peripheral soft-tissue protocol, not claiming the compounds are inactive in every other tissue. Bone, cartilage, peripheral nerve, and CNS repair remain outside the protocol’s mechanism-led scope.

When to Add NAD+

BPC-157 + TB-500 cover blood supply and cell movement, the two layers most soft-tissue injuries need first. NAD+ is the first add when those mechanisms are working but progress stalls, because repair cells still need enough cellular energy to build collagen and remodel tissue.

NAD+ from the start fits a chronic injury of six months or longer, post-surgical recovery, high training load, or recovery that feels systemically draining. Practitioner protocols use 50–250 mg IM about three times weekly in a separate syringe and site. NAD+ is acidic (pH 3–4), degrades peptides on contact, and can sting; room-temperature solution and a slow push reduce that discomfort.

The other layers are conditional. GHK-Cu fits poor load-bearing quality that points to collagen organization as the remaining bottleneck. KPV fits inflammation that keeps cycling back, such as swelling that returns after moderate activity despite four or more weeks; it pre-empts the inflammation switch (NF-κB).⁹

For all three layers at once, the Injury Recovery Protocol is the cleaner path than bolting compounds onto this stack one at a time.

Tell FoxAI about your injury and it builds the right protocol→

Phenotype Considerations

Chronic injuries of six months or longer. Established scar tissue and adapted blood-supply patterns can add bottlenecks beyond the vascular and migration layers this stack addresses. Practitioner protocols bring NAD+ in from the start and use the full 12-week cycle.

Post-surgical recovery. The convention defers the stack until the initial clotting window has settled, usually two weeks, unless the surgical team directs otherwise. Early new blood-vessel formation can complicate fresh surgical healing.

GLP-1 use or caloric deficit. Repair draws on energy and protein that a deficit restricts. NAD+ moves from a conditional layer to a first-line add, and the protein floor in Supporting Factors carries more weight.

WADA-tested athletes. TB-500 is prohibited, and BPC-157 is classified under WADA S0. Both have detectable metabolites, so the stack is incompatible with tested competition.

Supporting Factors

Peptides provide the repair signal. The raw materials come from nutrition and loading.

These inputs supply repair substrates and controlled mechanical loading. Peptide use does not replace physical therapy; new collagen still requires directional load to organize.

When Progress Stalls

The shape of the stall is more informative than an automatic dose increase.

Early improvement that levels off. The vascular and migration bottlenecks may have cleared while energy, collagen quality, or inflammation became rate-limiting. The matching layer is NAD+, GHK-Cu, or KPV.

Tissue warmth with falling energy. The repair signal is present, but the energy supply is lagging. Practitioner protocols review protein and sleep first, then add or tighten NAD+.

No change by week 3. Product identity, injection technique, and storage come before dose escalation. Reconstituted vials should remain refrigerated and protected from light; degradation can erase the expected response.

Scar remodeling does not improve. Confirm vial identity. The anti-scarring evidence belongs to full-length TB-4, not the TB-500 fragment; a mislabeled fragment cannot carry that claim.⁷

Safety & Considerations

Active cancer or malignancy within two years. Both peptides promote new blood-vessel formation, which could theoretically support an existing tumor’s blood supply. Practitioner protocols treat active treatment as a contraindication and the first two years after remission as a caution.

Pregnancy or breastfeeding. Neither peptide has safety data for these populations.

Proliferative retinopathy. New blood-vessel formation may worsen the underlying pathology.

Recent or planned surgery. Practitioner protocols wait until the initial clotting window has settled unless the surgical team directs otherwise.

Therapeutic anticoagulation, active autoimmune disease, or concurrent corticosteroids. These situations add specific interaction risks. Corticosteroids oppose the repair mechanisms the stack is meant to drive, while TB-500 changes immune-cell behavior in ways that may interact with autoimmune disease.

Conventional alternatives include physical therapy, NSAIDs, and corticosteroid injections. Each targets a different part of injury management and carries a different evidence and risk surface.

Regulatory & Legal Status

Neither BPC-157 nor TB-500 is FDA-approved for any use, and neither is an approved injury therapy. Regulatory status does not establish either safety or therapeutic failure.

FDA compounding status. In late 2023, the FDA placed both peptides on its Category 2 bulk drug substances list. In April 2026, it removed them after the original nominations were withdrawn. Both were then scheduled for Pharmacy Compounding Advisory Committee review in July 2026. This access status is changing and requires a current check.

WADA (sport) status. Both are prohibited at all times, in and out of competition. BPC-157 is classified under S0 (non-approved substances); TB-500 falls under S2 (peptide hormones and growth factors). Metabolites of both are detectable on testing, so the stack is not usable for any drug-tested athlete.

What Evidence Exists

BPC-157. A 2025 systematic review covers 36 studies: 35 preclinical and one clinical study with 12 patients.³ New blood-vessel formation, nitric oxide signaling, and FAK-paxillin repair-cell migration are well characterized; a hamstring-tendon Phase 2 RCT is recruiting. No completed modern RCT has measured injury recovery.

TB-500 and TB-4. Full-length TB-4 has human data from corneal-healing Phase 2/3 trials, cardiac and wound programs, and Phase 1 safety work.⁴ Those instruments studied the full-length protein. Their findings do not transfer automatically to the TB-500 fragment, which makes vial identity part of the evidence claim.

The combination. No human trial has tested the Wolverine Stack. One rat model found that BPC-157 + TB-4 restored function earlier than either compound alone.⁸ The human protocol remains a mechanism-led, practitioner-derived construction rather than a measured combination outcome.

FAQ

Related Topics

• BPC-157 + TB-500 Calculator — Reconstitution and per-dose math for both vials
• Wolverine Stack Guide — The narrative injury-recovery walkthrough and weekly timeline
• Injury Recovery Peptide Protocol — Five-compound framework adding NAD+, GHK-Cu, and KPV
• BPC-157 Guide — Standalone dosing, oral vs injectable, pharmacokinetics
• TB-500 / TB-4 Guide — Fragment vs full-length, certificate-of-analysis verification
• NAD+ Guide — Cellular energy support for stalled healing
• KLOW Dosage Calculator — Four-peptide blend that includes BPC-157 and TB-4 for skin and tissue repair
• Peptide Calculator — General-purpose reconstitution and dosing calculator
• Where to Inject Peptides — Near-injury vs systemic injection routing

References

¹ BPC-157 angiogenic signaling — VEGFR2–Akt–eNOS activation, nitric oxide bioavailability, endothelial sprouting, anti-cytokine modulation: PMC8275860

² TB-500 / TB-4 G-actin sequestration — actin-monomer binding maintains the reserve pool repair cells draw on for migration; mass-action pharmacodynamics favor bolus dosing: PubMed 12581423

³ BPC-157 systematic review — 36 studies (35 preclinical, 1 clinical with 12 patients); VEGF upregulation, eNOS activation, FAK-paxillin cascade. Vasireddi N et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine." HSS J. 2025. PMC12313605

⁴ TB-4 Phase 1 safety — 84 healthy volunteers tolerated recombinant thymosin beta-4 up to 25 μg/kg daily for 10 days with no serious adverse events. Wang D et al. Ann Transl Med. 2021;9(15):1232. PMC8419156

⁵ TB-4 local-versus-systemic tissue concentration — free systemic TB-4 at a matched total dose produced no functional improvement versus a locally-targeted formulation; systemic dilution dropped tissue concentration below threshold: PMC5396927

⁶ BPC-157 tendon outgrowth — FAK-paxillin signaling promotes repair-cell outgrowth and migration. Chang et al. J Appl Physiol. 2011. PubMed 21030672

⁷ TB-4 / TB-500 mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa) and the TB-500 fragment (residues 17–23) in marketed products. Esposito M et al. Drug Test Anal 2012. PubMed 22962027

⁸ Combined BPC-157 + TB-4 — combined administration restored contractile function earlier than either compound alone. Rahman OF et al. "Therapeutic Peptides in Orthopaedics." J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). PMC12753158

⁹ KPV NF-κB inhibition — blocks nuclear translocation of NF-κB, suppresses inflammatory transcription while preserving normal immune signaling: PubMed 18061177

¹⁰ Collagen supplementation — systematic review of collagen peptide effects on synthesis and recovery; pre-exercise timing. Kirmani BH et al. Amino Acids. 2021. PMC8521576

¹¹ BPC-157 and tumor risk — narrative review of regeneration versus cancer risk; preclinical data suggest anti-tumorigenic properties in some contexts. McGuire FP et al. "Regeneration or Risk?" Curr Rev Musculoskelet Med. 2025;18(12):611–619. PMC12446177

This content is for educational purposes only. BPC-157 and TB-500 are not FDA-approved injury therapies. No human trial has tested the combination; the protocols above come from component mechanisms and practitioner observation. Active cancer, autoimmune disease, and medications that affect immune function or coagulation add risks that require individual clinical assessment.